Extended Data Fig. 5: Added value of the presence of engineered B cells in NeoScreen - Increased sensitivity of NeoScreen over peptides alone (Primed15) for antigen discovery.
From: Sensitive identification of neoantigens and cognate TCRs in human solid tumors
a, Comparison of NeoScreen to Primed, based on the addition of peptide pools (in the absence of APC) at the initiation of TIL cultures. b, Potency of re-stimulation of TILs by Primed versus NeoScreen for patient 7. Frequency of neoantigen-specific T cells was determined by IFNγ Spot Forming Unit per 105 cells (mean±SD of duplicate) following re-challenge with PHLPP2N1186Y peptide. c, Magnitude of tumor antigen-specific T cells determined by IFNγ Spot Forming Unit per 105 cells (n = 9 epitopes) obtained with NeoScreen, Primed or conventional cultures. Box plots represent median (line), 25% and 75% confidence limit (box limits) and min to max (whiskers). d, Cumulative analysis of the frequency of antigen-specific T cells (n = 9 tumor epitopes, Supplementary Table 4) in Primed (x-axis) and NeoScreen (y-axis) cultures of patients 1, 6, 7, 8 and 9 (Supplementary Table 2), by IFNγ Spot Forming Unit per 105 cells. For c and d, the background levels of IFNγ Spot Forming Unit by cognate negative controls (TILs alone) were subtracted and the highest values between 1xNeoScreen and 2xNeoScreen are considered. P-values were determined with one-tailed paired t-tests and data are displayed in logarithmic scale.
